Goeltz II Robert C.

Chief Financial Officer

Goeltz II Robert C. has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: May 12, 2026.

On the most recent filing, Goeltz II Robert C. is listed as Chief Financial Officer at Arcus Biosciences, Inc. Inside the rolling window, Goeltz II Robert C. reported no open-market purchases and 6 open-market sales totaling $856K in RCUS. The largest disclosed transaction in the window is a sale of 7,763 RCUS shares on May 11, 2026, worth $199K.

Companies traded

Other insiders at RCUS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$856K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
RCUSSale$199KMay 12SEC ↗
RCUSSale$153KJan 2SEC ↗
RCUSSale$147KDec 18SEC ↗
RCUSSale$132KDec 18SEC ↗
RCUSSale$125KNov 26SEC ↗
RCUSSale$100KOct 29SEC ↗
Showing 1–6 of 6
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Goeltz II Robert C. made?

Goeltz II Robert C. has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.

Which companies does Goeltz II Robert C. trade?

Goeltz II Robert C. has filed SEC Form 4 disclosures for 1 company, including RCUS.

When was Goeltz II Robert C.'s most recent SEC Form 4 filing?

Goeltz II Robert C.'s most recent SEC Form 4 filing on Tracefour is dated May 12, 2026.

What is Goeltz II Robert C.'s job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Goeltz II Robert C. is listed as Chief Financial Officer.

What is Goeltz II Robert C.'s total buy and sell value in the current window?

Inside the rolling retention window, Goeltz II Robert C. bought $0 and sold $856K based on SEC Form 4 filings.

What was Goeltz II Robert C.'s largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 7,763 RCUS shares on 2026-05-11, worth $199K, per SEC Form 4 filings.